CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
irinotecan hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00617539
NCT00617539Phase 2Completed

A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation

University of California, San Francisco·interventional·Posted Feb 18, 2008·Updated Apr 20, 2018

In Brief

A Phase 2 clinical trial evaluating irinotecan hydrochloride and temozolomide for Breast Cancer and Metastatic Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving irinotecan together with temozolomide and to see how well it works in treating patients with breast cancer who have received previous treatment for brain metastases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2008
Enrollment StartFeb 1, 2005
Primary CompletionJan 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 18.4 years ago

Interventions

irinotecan hydrochloridedrug

temozolomidedrug